244 related articles for article (PubMed ID: 34713248)
21. Laboratory investigation of hemoglobinopathies and thalassemias: review and update.
Clarke GM; Higgins TN
Clin Chem; 2000 Aug; 46(8 Pt 2):1284-90. PubMed ID: 10926923
[TBL] [Abstract][Full Text] [Related]
22. Delta beta thalassemia and hereditary persistence of fetal hemoglobin.
Bollekens JA; Forget BG
Hematol Oncol Clin North Am; 1991 Jun; 5(3):399-422. PubMed ID: 1713909
[TBL] [Abstract][Full Text] [Related]
23. Prevalence of globin gene modifiers encountered in fetuses during antenatal diagnosis of hemoglobinopathies.
Mehta P; Sawant P; Gorivale M; Nadkarni A; Colah R; Mukherjee MB
Int J Lab Hematol; 2020 Aug; 42(4):482-491. PubMed ID: 32412692
[TBL] [Abstract][Full Text] [Related]
24. [Regulation of γ-globin gene expression and its clinical applications].
Ju JY; Zhao Q
Yi Chuan; 2018 Jun; 40(6):429-444. PubMed ID: 29959116
[TBL] [Abstract][Full Text] [Related]
25. δ-Hemoglobinopathies in Thailand: screening, molecular basis, genotype-phenotype interaction, and implication for prevention and control of thalassemia.
Singha K; Fucharoen G; Fucharoen S
Ann Hematol; 2021 Aug; 100(8):1953-1963. PubMed ID: 33834283
[TBL] [Abstract][Full Text] [Related]
26. Hemoglobinopathies.
Atweh GF; DeSimone J; Saunthararajah Y; Fathallah H; Weinberg RS; Nagel RL; Fabry ME; Adams RJ
Hematology Am Soc Hematol Educ Program; 2003; ():14-39. PubMed ID: 14633775
[TBL] [Abstract][Full Text] [Related]
27. Distinct phenotypic expression associated with a new hyperunstable alpha globin variant (Hb heraklion, alpha1cd37(C2)Pro>0): comparison to other alpha-thalassemic hemoglobinopathies.
Traeger-Synodinos J; Papassotiriou I; Metaxotou-Mavrommati A; Vrettou C; Stamoulakatou A; Kanavakis E
Blood Cells Mol Dis; 2000 Aug; 26(4):276-84. PubMed ID: 11042028
[TBL] [Abstract][Full Text] [Related]
28. DNA methylation patterns of β-globin cluster in β-thalassemia patients.
Bao X; Zuo Y; Chen D; Zhao C
Clin Epigenetics; 2020 Dec; 12(1):187. PubMed ID: 33272312
[TBL] [Abstract][Full Text] [Related]
29. Fetal hemoglobin chemical inducers for treatment of hemoglobinopathies.
Testa U
Ann Hematol; 2009 Jun; 88(6):505-28. PubMed ID: 19011856
[TBL] [Abstract][Full Text] [Related]
30. CRISPR/Cas9-based epigenome editing: An overview of dCas9-based tools with special emphasis on off-target activity.
Tadić V; Josipović G; Zoldoš V; Vojta A
Methods; 2019 Jul; 164-165():109-119. PubMed ID: 31071448
[TBL] [Abstract][Full Text] [Related]
31. Effects of alpha-thalassemia-2 on the developmental changes of hematological values in children with sickle cell disease from Georgia.
Felice AE; McKie KM; Cleek MP; Marino EM; Kutlar A; McKie VC
Am J Hematol; 1987 Aug; 25(4):389-400. PubMed ID: 2441597
[TBL] [Abstract][Full Text] [Related]
32. Targeted deletion of BCL11A gene by CRISPR-Cas9 system for fetal hemoglobin reactivation: A promising approach for gene therapy of beta thalassemia disease.
Khosravi MA; Abbasalipour M; Concordet JP; Berg JV; Zeinali S; Arashkia A; Azadmanesh K; Buch T; Karimipoor M
Eur J Pharmacol; 2019 Jul; 854():398-405. PubMed ID: 31039344
[TBL] [Abstract][Full Text] [Related]
33. Gene therapy in thalassemia and hemoglobinopathies.
Breda L; Gambari R; Rivella S
Mediterr J Hematol Infect Dis; 2009 Nov; 1(1):e2009008. PubMed ID: 21415990
[TBL] [Abstract][Full Text] [Related]
34. [Regulation of the β-globin gene family expression, useful in the search for new therapeutic targets for hemoglobinopathies].
Scheps KG; Varela V
Medicina (B Aires); 2016; 76(6):383-389. PubMed ID: 27959850
[TBL] [Abstract][Full Text] [Related]
35. Modification of hemoglobin H disease by sickle trait.
Matthay KK; Mentzer WC; Dozy AM; Kan YW; Bainton DF
J Clin Invest; 1979 Oct; 64(4):1024-32. PubMed ID: 479366
[TBL] [Abstract][Full Text] [Related]
36. Ten Years of Routine α- and β-Globin Gene Sequencing in UK Hemoglobinopathy Referrals Reveals 60 Novel Mutations.
Henderson SJ; Timbs AT; McCarthy J; Gallienne AE; Proven M; Rugless MJ; Lopez H; Eglinton J; Dziedzic D; Beardsall M; Khalil MS; Old JM
Hemoglobin; 2016; 40(2):75-84. PubMed ID: 26635043
[TBL] [Abstract][Full Text] [Related]
37. Omics Studies in Hemoglobinopathies.
Katsantoni E
Mol Diagn Ther; 2019 Apr; 23(2):223-234. PubMed ID: 30712217
[TBL] [Abstract][Full Text] [Related]
38. Fetal globin gene repressors as drug targets for molecular therapies to treat the β-globinopathies.
Suzuki M; Yamamoto M; Engel JD
Mol Cell Biol; 2014 Oct; 34(19):3560-9. PubMed ID: 25022757
[TBL] [Abstract][Full Text] [Related]
39. Prenatal diagnosis of hemoglobinopathies: comparison of the results obtained by isoelectric focusing of hemoglobins and by chromatography of radioactive globin chains.
Dubart A; Goossens M; Beuzard Y; Monplaisir N; Testa U; Basset P; Rosa J
Blood; 1980 Dec; 56(6):1092-9. PubMed ID: 6159934
[TBL] [Abstract][Full Text] [Related]
40. Implication of globin gene expression, hemoglobin F and hemoglobin E levels on β-thalassemia/Hb E disease severity.
Siriworadechkul S; Jindadamrongwech S; Chuncharunee S; Aupparakkitanon S
Ann Clin Lab Sci; 2014; 44(4):437-42. PubMed ID: 25361929
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
